ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Phase II studies demonstrated that adding the immunomodulatory agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowakowski, Grzegorz S., Chiappella, Annalisa, Gascoyne, Randy D., Scott, David W., Zhang, Qingyuan, Jurczak, Wojciech, Özcan, Muhit, Hong, Xiaonan, Zhu, Jun, Jin, Jie, Belada, David, Bergua, Juan Miguel, Piazza, Francesco, Mócikova, Heidi, Molinari, Anna Lia, Yoon, Dok Hyun, Cavallo, Federica, Tani, Monica, Yamamoto, Kazuhito, Izutsu, Koji, Kato, Koji, Czuczman, Myron, Hersey, Sarah, Kilcoyne, Adrian, Russo, Jacqueline, Hudak, Krista, Zhang, Jingshan, Wade, Steve, Witzig, Thomas E., Vitolo, Umberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078325/
https://www.ncbi.nlm.nih.gov/pubmed/33621109
http://dx.doi.org/10.1200/JCO.20.01366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078325/
https://www.ncbi.nlm.nih.gov/pubmed/33621109
http://dx.doi.org/10.1200/JCO.20.01366

Ejemplares similares